Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026)

Bicara Therapeutics has reported Free Cash Flow for 4 years, with the latest figure at -$37.6 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 33.67% year-over-year to -$37.6 million; the trailing twelve-month figure through Mar 2026 stood at -$116.6 million (down 31.97% YoY), and the FY2025 full-year result was -$107.1 million, down 43.16% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$37.6 million, down from -$24.1 million in the prior quarter.
• The five-year high for Free Cash Flow was -$8.5 million in Q4 2023, with the low at -$37.6 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$22.8 million across 4 years, with a median of -$24.9 million in 2025.
• Annual changes were most pronounced in 2024 — Free Cash Flow tumbled 254.96% — and 2025, when it climbed 19.78%.
• Bicara Therapeutics' Free Cash Flow stood at -$8.5 million in 2023, then plunged by 254.96% to -$30.1 million in 2024, then rose by 19.78% to -$24.1 million in 2025, then tumbled by 55.73% to -$37.6 million in 2026.
• The last three Free Cash Flow figures came in at -$37.6 million (Q1 2026), -$24.1 million (Q4 2025), and -$29.3 million (Q3 2025), per Business Quant data.